
Sappi Casting and Release Announces New Textures and Collaborative Product Launch Ahead of
BOSTON--(BUSINESS WIRE)-- Sappi North America, Inc., a leading producer and supplier of diversified paper, packaging products and dissolving wood pulp, is preparing for the interzum 2025 exhibition with six new Ultracast textures and a new collaborative product launch. The exhibition will take place next week – May 20 – 23 – in Cologne, Germany.
Visitors to the Sappi booth (Hall 6.1 Booth E-048) will be immersed in a sensory experience with surfacing solutions that demonstrate the impact of how we perceive and experience a variety of materials through natural looking design and our sense of touch. The decorative laminate texture six-pack will include new or recently launched textures, including:
Canaletto: Canaletto is a new woodgrain texture with a natural, all-over design featuring meticulous details and a well-balanced rhythmic grain pattern. The realistic details, beautiful shimmer, and satiny touch make Canaletto stand out, evoking a soft, precise richness of noble wood.
Circuit: The complex interconnections and patterns on electronic components inspire Circuit. Its peaks and valleys look like traces and pathways woven or etched onto its surface. When you examine its haptic surface more closely, you can see a delicate network of lines that resemble conductive routes punctuated by geometric shapes.
City: City is an evolution of the Sappi texture Urban, with a refined stone character for a more contemporary appeal. With an expanded scale, softened and adapted to trendy stones like travertine and limestone, City is versatile and can beautifully fit many other décors like marble, concrete, clay and granite.
Matte Luxor: Matte Luxor is a decorative laminate version of our textile texture Luxor. The dual gloss surface creates a woven appearance of squares and diamonds. The ultra-fine lines produce a warp-and-weft effect, adding an easy, subtle sheen to the surface design. Matte Luxor's haptic is reminiscent of a pleasing woven engineered finish. When touched, the technical texture has a multidirectional sensory effect: one direction has a gliding smoothness, and the other has a slight roughness.
Mokka Vintage: Mokka Vintage exudes a bold, industrial aesthetic with its ultra-flat finish and intentionally weathered appearance. Mokka Vintage's dual finish creates extremes in light and dark qualities, giving the material a raw and rough edge. Deliberately incorporated subtle scuffs, scratches, and irregularities suggest a history of wear and resilience.
Vita: Vita, our newest organic texture, features a nicely refined ribbed finish with subtle undulations that exhibit a vibrant play of glimmer and shadow, a vivid sheen that moves with the light. Vita enables unlimited design freedom in interiors with a surface that blends perfectly into the elevated aesthetics of industrial stainless steel and the expressive elegance of statement pieces.
'When creating new textures, we are constantly evaluating what is the most important to consumers – haptics, aesthetics, and function,' says Mark Hittie, Director of Release Business Strategy for Sappi North America. 'We are proud to showcase this new laminate texture six-pack, which combines design with performance. We strive to push the boundaries of texture, with the user experience always top of mind.'
In addition to these six new textures, Sappi is announcing a collaborative product launch with Upco SRL. UpcoXtouch, Texture by Sappi, is a three-dimensional textured surfacing solution that provides high-wear and anti-fingerprint performance to decorative laminates, including worktops, countertops, and kitchen cabinetry.
'We strongly believe in this collaboration,' says Florian von Kuczkowski, COO of Upco SRL. 'Combining Upco's innovative functional coating solutions with Sappi's aesthetically pleasing and authentic-to-the-touch textures answers the need of laminators for a textured surface with highly functional properties.'
UpcoXtouch will be featured at both Upco's and Sappi's booths during interzum 2025.
Learn more about Sappi's Textures here.
About Sappi North America, Inc.
Headquartered in Boston, Massachusetts, Sappi North America, Inc., is a leader in converting wood fiber into superior products that are used worldwide. Sappi NA has a corporate office in Portland, Maine and mills in Skowhegan and Westbrook, Maine, Cloquet, Minnesota, and Matane, Quebec, along with a dedicated Technology Center and Sheeting Facility. Sappi NA employs approximately 2,100 people in the United States and Canada.
Sappi NA uses a renewable, recyclable natural source – woodfibre – to create packaging, specialty papers, graphic papers, and pulp that make everyday products more sustainable. Sappi supports sustainable forestry and sustainable manufacturing to mitigate climate change, protect biodiversity and improve soil and water quality.
Sappi North America is a subsidiary of Sappi Limited (JSE), a global company headquartered in Johannesburg, South Africa, with more than 12,000 employees and manufacturing operations on three continents in seven countries and customers in over 150 countries. To learn more, visit www.sappi.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
25 minutes ago
- Business Wire
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 'I was very encouraged to see that nearly half of patients had a confirmed response to the casdatifan plus cabozantinib combination despite short follow-up,' said Toni K. Choueiri, M.D., director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber, the Jerome and Nancy Kohlberg Chair and professor of medicine at Harvard Medical School, and lead investigator of ARC-20. 'Casdatifan plus cabozantinib was well tolerated, and the safety profile was consistent with that of either agent alone, supporting their potential as a combination therapy. I look forward to enrolling patients into the PEAK-1 trial as soon as it is open.' 'The initial data for casdatifan plus cabozantinib in the ARC-20 study have already exceeded the historic benchmarks for either agent alone, as well as that of another HIF-2a inhibitor plus cabozantinib in the same second-line setting,' said Terry Rosen, Ph.D., chief executive officer of Arcus. 'These data serve as the proof of concept for PEAK-1, which will be initiated in the coming weeks and is designed to generate evidence to change the standard of care for people who have progressed on prior immunotherapy treatment.' ARC-20 is a Phase 1/1b dose-escalation and expansion study that includes a cohort evaluating once-daily 100mg of casdatifan plus 60mg of cabozantinib in patients with ccRCC who had progressed on prior immunotherapy. At the time of the data cutoff (DCO, March 14, 2025), 42 participants were evaluable for safety, and 24 reached at least 12 weeks of follow-up and were evaluable for efficacy. Among the safety-evaluable population (N=42), most participants (79%) had an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factor of intermediate or poor. Nearly half (46%) of the efficacy-evaluable population (N=24) achieved a confirmed response per RECIST 1.1, and only one patient had primary progressive disease. The vast majority of the efficacy-evaluable population remains on treatment. In the safety-evaluable population, no unexpected safety risks were identified at the time of DCO, and casdatifan plus cabozantinib had an acceptable safety profile with no meaningful overlapping toxicity for the two drugs. Only two patients discontinued any drug, and no patients discontinued treatment with both drugs. The incidence of treatment-emergent adverse events (TEAEs) with casdatifan, particularly anemia and hypoxia, was similar to TEAEs observed with casdatifan monotherapy, and there were no casdatifan-related Grade 4 or 5 adverse events. The incidence of TEAEs associated with each drug was consistent with what is expected for each drug alone. A summary of the efficacy and safety results is below. Arcus is pursuing a broad development program in both the immuno-oncology (IO)-naive and post-IO settings with differentiated combinations to maximize the opportunity for casdatifan in ccRCC. These studies include: Arcus's planned Phase 3 study, PEAK-1, which will evaluate casdatifan plus cabozantinib versus cabozantinib monotherapy as a first- or second-line treatment in patients with metastatic ccRCC who have previously received anti-PD-1/PD-L1 therapy. The primary endpoint will be PFS with a key secondary endpoint of overall survival. eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca, which will evaluate casdatifan plus volrustomig, an investigational anti-PD-1/CTLA-4 bispecific antibody, as first-line treatment for participants with ccRCC. ARC-20, which includes three cohorts evaluating casdatifan in earlier-line settings, including casdatifan plus zimberelimab in first-line ccRCC, casdatifan monotherapy in favorable risk ccRCC, and casdatifan monotherapy in immunotherapy-experienced, TKI-naive settings. Investors may dial in to the conference call at +1 404 975 4839 (local) or +1 833 470 1428 (toll-free) using Conference ID: 446724 on Monday, June 2, 2025, at 5:00 AM PT / 7:00 AM CT. Participants may also register for the call online using the following link: To access the live webcast and accompanying slide presentation, please visit the 'Investors & Media' section of the Arcus Biosciences website at A replay will be available following the live event. About Casdatifan (AB521) Casdatifan is a small-molecule inhibitor of HIF-2a, a transcription factor responsible for activating multiple tumor growth pathways in hypoxic and pseudo-hypoxic tumor environments. By selectively binding HIF-2a, casdatifan is designed to shut down hypoxic oncogenesis and key oncogenic pathways, which leads to cancer cell death. Clear cell renal cell carcinoma is almost universally associated with HIF-2a dysregulation. Casdatifan is currently being evaluated in ARC-20, a Phase 1/1b study in renal cell carcinoma. Casdatifan is an investigational molecule. Approval from any regulatory authority for its use has not been received, and its safety and efficacy have not been established. About RCC According to the American Cancer Society, kidney cancer is among the top 10 most commonly diagnosed forms of cancer among both men and women in the U.S., and an estimated 80,980 Americans will be diagnosed with kidney cancer in 2025. Clear cell RCC is the most common type of kidney cancer in adults. If detected in its early stages, the five-year survival rate for RCC is high; for patients with advanced or late-stage metastatic RCC, however, the five-year survival rate is only 18%. In 2022, approximately 32,200 patients with advanced kidney cancer required systemic therapy in the U.S., with over 20,000 patients receiving first-line treatment. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit Forward Looking Statements This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Choueiri's and Dr. Rosen's quotes and statements regarding: the potency, efficacy or safety of casdatifan, including its potential for a best-in-class profile and potential as a combination therapy; and Arcus's development plans for the casdatifan program, including expected timing and design for new studies and cohorts and plans for generating data to support initiation of future studies. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus's actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to risks associated with: interim data not being replicated in future studies evaluating the same investigational molecules or regimen; the unexpected emergence of adverse events or other undesirable side effects with casdatifan; risks associated with manufacturing or supplying product for such clinical trials; uncertainties in timelines associated with the conduct of clinical studies and with respect to the regulatory application process; difficulties associated with the management of the collaboration activities with our strategic partners or expanded clinical programs; changes in the competitive landscape for Arcus's programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the 'Risk Factors' section of Arcus's most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law. The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.


Business Upturn
an hour ago
- Business Upturn
Announcing Balaji Karumanchi as Founder & CEO of Excelhire – The AI-Agentic Hiring Intelligence Platform
About Balaji Karumanchi Balaji Karumanchi is a seasoned entrepreneur and visionary technologist with over two decades of experience in enterprise solutions, AI innovation, and HR tech. With Excelhire, he's redefining how organizations approach talent acquisition — with intelligence, automation, and a relentless focus on hiring outcomes. About Excelhire Excelhire is a next-gen hiring platform powered by a system of AI Agents that automate and optimize the recruitment process from end to end. Designed for modern hiring teams, Excelhire delivers faster, fairer, and more efficient hiring through continuous, intelligent automation. Click here for Media Contact Details Submit your press release Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Business Wire is an American company that disseminates full-text press releases from thousands of companies and organizations worldwide to news media, financial markets, disclosure systems, investors, information web sites, databases, bloggers, social networks and other audiences.


Business Wire
an hour ago
- Business Wire
TMCI Deadline: Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024. Treace Medical describes itself as a 'medical technology company focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities.' For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Treace Medical Concepts, Inc. (NASDAQ: TMCI) Misled Investors Regarding its Business Operations. According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System (the 'Lapiplasty'); (2) as a result, Treace Medical's revenue declined and Treace Medical needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants' positive statements about Treace Medical's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 10, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.